Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata
This study is ongoing, but not recruiting participants.
Sponsored by: University of California, San Francisco
Information provided by: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT00187577
  Purpose

This is a single center, randomized, investigator-masked study to determine the efficacy and safety of latanaprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients who have lost their eyelashes due to alopecia areata. These medications are FDA-approved as eyedrops for patients with glaucoma who have been noted to grow longer, darker, and thicker eyelashes with their use. In this study, patients will be asked to apply these solutions to the affected eyelid margins of one eye with a sterile cotton-tipped applicator once a day.


Condition Intervention
Alopecia Areata
Drug: Latanoprost (Xalatan)
Drug: Bimatoprost (Lumigan)

MedlinePlus related topics: Hair Diseases and Hair Loss
Drug Information available for: Latanoprost Bimatoprost
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Single Blind, Dose Comparison, Parallel Assignment, Efficacy Study
Official Title: Efficacy and Safety of Latanoprost (Xalatan) and Bimatoprost (Lumigan) Ophthalmic Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata

Further study details as provided by University of California, San Francisco:

Primary Outcome Measures:
  • Eyelash growth in response to topical application of latanoprost or bimatoprost to the eyelid margins of patients with alopecia areata; eyelid photographs and eyelash length will be documented at 8 week intervals.

Estimated Enrollment: 20
Study Start Date: June 2005
Estimated Study Completion Date: March 2006
Detailed Description:

This is a pilot, single-center, randomized, investigator-masked study to evaluate the efficacy and safety of latanoprost (Xalatan) ophthalmic solution compared to bimatoprost (Lumigan) ophthalmic solution in patients with eyelash loss due to alopecia areata. This is a collaborative study between the Departments of Dermatology and Ophthalmology at UCSF. Patients will be randomized to receive either latanoprost or bimatoprost. Patients will be instructed to apply latanoprost or bimatoprost to the affected eyelid margins of one eye using a sterile cotton-tipped applicator once a day (similar to the application of eyeliner). The untreated eye will serve as a control. When substantial eyelash growth is noted in the treated eye, patients will be instructed to decrease application to once a week. Patients will be seen every four weeks in the Department of Dermatology. In addition, eyelash growth will be assessed in the Beckman Vision Center where eyelash length will be measured, and photographs will be taken at baseline, 2 months, and 4 months. Intraocular pressure will be documented at baseline and at each visit to the Beckman Vision Center. The study will be conducted over four months.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Males and females in good general health, ages 18-70.
  • Patients with alopecia areata who have had 50% or more eyelash loss for 6 months or longer.

Exclusion Criteria:

  • Any pre-existing eye disorder that would preclude use of a topical agent around the eyes (e.g. infection, inflammation, recent surgery.)
  • Subjects with limited close vision who cannot see their eyelid margin clearly.
  • Immunosuppressed state.
  • Women who are pregnant or who are trying to become pregnant, or are breast-feeding.
  • Patients with known allergy to latanoprost or bimatoprost, other prostaglandin F-2a or related drugs, or to benzalkonium.
  • Unable to read or follow instructions.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00187577

Locations
United States, California
University of California, San Francisco
San Francisco, California, United States, 94117
Sponsors and Collaborators
University of California, San Francisco
Investigators
Principal Investigator: Vera H. Price, M.D. Professor, University of California, San Francisco Department of Dermatology
Principal Investigator: Robert L. Stamper, M.D. Professor, University of California, San Francisco Department of Ophthalmology
  More Information

Publications:
Study ID Numbers: H7285-26596-01
Study First Received: September 13, 2005
Last Updated: March 17, 2006
ClinicalTrials.gov Identifier: NCT00187577  
Health Authority: United States: Food and Drug Administration

Keywords provided by University of California, San Francisco:
Alopecia areata
Eyelash growth
Latanoprost
Bimatoprost

Study placed in the following topic categories:
Pathological Conditions, Anatomical
Alopecia Areata
Alopecia areata
Bimatoprost
Skin Diseases
Alopecia
Latanoprost

Additional relevant MeSH terms:
Hair Diseases
Hypotrichosis
Therapeutic Uses
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009